On This Day in Health: May 6, 2020
On May 6, 2020, the U.S. Food and Drug Administration approved capmatinib, marketed as Tabrecta, for adults with metastatic non-small cell lung cancer whose tumors had mutations leading to MET exon 14 skipping. It was the first FDA-approved treatment specifically directed at that molecularly defined group. The agency also approved a companion diagnostic test to identify the relevant alteration. The decision illustrated a changing approach to cancer care: the site of a tumor still mattered, but its molecular features could also determine which medicine offered a reasonable treatment option. Testing and treatment were parts of the same advance.
MET is involved in signaling that helps regulate cell growth. Changes that cause exon 14 skipping can disturb the normal regulation of the MET protein, allowing growth signals to persist. Capmatinib is a kinase inhibitor intended to block that signaling activity. The drug was taken orally, but the convenience of a tablet did not make it suitable for every person with lung cancer. The original indication required a particular tumor alteration detected by an approved test. A diagnosis of non-small cell lung cancer alone was therefore insufficient to establish eligibility. The milestone belonged to precision oncology rather than a universal treatment for the disease.
The accelerated approval rested on evidence of tumor response and how long those responses lasted. The supporting GEOMETRY mono-1 study included both previously treated patients and patients who had not received treatment for their advanced disease. Some tumors shrank substantially, giving the agency evidence of activity in a population with an unmet need. Such results do not mean that every patient responds or that tumor shrinkage is identical to a cure. Accelerated approval also carries a responsibility to confirm clinical benefit through further research. Safety required attention as well: swelling, nausea and fatigue were among common adverse reactions, and serious lung inflammation and liver injury were important risks.
The broader significance of May 6 was the connection between a laboratory result and a practical therapeutic choice. Molecular testing can reveal an opportunity that cannot be inferred simply from a scan or the organ where cancer started. It also introduces requirements for adequate samples, dependable analysis and interpretation by a clinical team. Targeted medicines can encounter resistance, and their benefits must be weighed against adverse effects and the patient's circumstances. The 2020 decision expanded the options available for one defined form of lung cancer while reinforcing the need for careful selection. Its anniversary records a step toward more individualized care, with the evidence and limitations that accompany that approach.
The original approval required mutations leading to MET exon 14 skipping.
An approved companion diagnostic helped identify eligible tumors.
Capmatinib blocks signaling through the MET kinase.
The decision used the accelerated approval pathway and tumor-response evidence.
A targeted tablet still required monitoring for potentially serious adverse effects.
The milestone linked molecular testing with a specific treatment option.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.